A potential new weapon against heart disease: PCSK9 inhibitors - Science in the News
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design - IRBM
Evolocumab becomes first PCSK9 inhibitor to be approved to prevent MI in USA
An End to Heart Disease? Not Quite - The New York Times
Why Merck's PCSK9 Inhibitors Are a Big Deal - Drug Hunter
PCSK9 inhibitors for COVID‐19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia - Vuorio - 2021 - Journal of Internal Medicine - Wiley Online Library
PCSK9 inhibitor significantly reduced CV risk in ASCVD patients in FOURIER outcomes study - PACE-CME
PCSK9 and its Inhibitors: A new approach in lipid lowering therapy | BioVendor R&D
PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time? - Minneapolis Heart Institute Foundation
The Evolving Future of PCSK9 Inhibitors - ScienceDirect
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Molecules | Free Full-Text | PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs | HTML
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy | Future Medicinal Chemistry
PCSK9 Inhibitors: What You Need to Know — tl;dr pharmacy
Can the third PCSK9 drug succeed where the first two failed? - Features - MM+M - Medical Marketing and Media
Cholesterol-Lowering PCSK9 Inhibitors Near Market Entry
Action of PCSK9 inhibitor on LDL receptor - Stock Image - C026/3524 - Science Photo Library
PCSK9 inhibitors: A new era of lipid lowering therapy
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions - ScienceDirect
SciELO - Brasil - PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Mastering the Art of Prior Authorization to Improve Patient Access to PCSK9 Inhibitors - Integrity CE
A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α - eBioMedicine
